TY - JOUR
T1 - The phytochemical bergenin enhances T helper 1 responses and anti-mycobacterial immunity by activating the MAP kinase pathway in macrophages
AU - Dwivedi, Ved P.
AU - Bhattacharya, Debapriya
AU - Yadav, Vinod
AU - Singh, Dhiraj K.
AU - Kumar, Santosh
AU - Singh, Mona
AU - Ojha, Durbadal
AU - Ranganathan, Anand
AU - Van Kaer, Luc
AU - Chattopadhyay, Debprasad
AU - Das, Gobardhan
N1 - Publisher Copyright:
© 2017 Dwivedi, Bhattacharya, Yadav, Singh, Kumar, Singh, Ojha, Ranganathan, Van Kaer, Chattopadhyay and Das.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Tuberculosis (TB) remains one of the greatest health concerns worldwide, which has hindered socioeconomic development in certain parts of the world for many centuries. Although current TB therapy, "Directly Observed Treatment Short-course," is effective, it is associated with unwanted side effects and the risk for the generation of drug-resistant organisms. The majority of infected individuals successfully confine the mycobacterial organisms and remain asymptotic unless immune responses are perturbed. Thus, host immunity can protect against TB and immunomodulation is therefore an attractive therapeutic option. Previous studies have shown that TNF-α and Nitric Oxide (NO) in conjunction with IFN-γ-producing T helper 1 (Th1) cells play critical roles in host protection against TB. Here, we show that bergenin, a phytochemical isolated from tender leaves of Shorea robusta, activates the MAP kinase and ERK pathways and induces TNF-α, NO and IL-12 production in infected macrophages. We further show that bergenin induces Th1 immune responses and potently inhibits bacillary growth in a murine model of Mycobacterium tuberculosis infection. These findings identify bergenin as a potential adjunct to TB therapy.
AB - Tuberculosis (TB) remains one of the greatest health concerns worldwide, which has hindered socioeconomic development in certain parts of the world for many centuries. Although current TB therapy, "Directly Observed Treatment Short-course," is effective, it is associated with unwanted side effects and the risk for the generation of drug-resistant organisms. The majority of infected individuals successfully confine the mycobacterial organisms and remain asymptotic unless immune responses are perturbed. Thus, host immunity can protect against TB and immunomodulation is therefore an attractive therapeutic option. Previous studies have shown that TNF-α and Nitric Oxide (NO) in conjunction with IFN-γ-producing T helper 1 (Th1) cells play critical roles in host protection against TB. Here, we show that bergenin, a phytochemical isolated from tender leaves of Shorea robusta, activates the MAP kinase and ERK pathways and induces TNF-α, NO and IL-12 production in infected macrophages. We further show that bergenin induces Th1 immune responses and potently inhibits bacillary growth in a murine model of Mycobacterium tuberculosis infection. These findings identify bergenin as a potential adjunct to TB therapy.
KW - Bergenin
KW - Immunomodulation
KW - Mycobacterium tuberculosis
KW - T cells
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85027495779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027495779&partnerID=8YFLogxK
U2 - 10.3389/fcimb.2017.00149
DO - 10.3389/fcimb.2017.00149
M3 - Article
C2 - 28507951
AN - SCOPUS:85027495779
SN - 2235-2988
VL - 7
JO - Frontiers in cellular and infection microbiology
JF - Frontiers in cellular and infection microbiology
IS - MAY
M1 - 149
ER -